Total Payments
$370,162
2024 Payments
$12,306
Companies
24
Transactions
146
Medicare Patients
844
Medicare Billing
$76,292
Payment Breakdown by Category
Consulting$254,632 (68.8%)
Other$60,480 (16.3%)
Travel$50,431 (13.6%)
Research$3,200 (0.9%)
Food & Beverage$1,251 (0.3%)
Royalty/License$167.28 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $254,632 | 79 | 68.8% |
| Travel and Lodging | $50,431 | 26 | 13.6% |
| Honoraria | $36,164 | 15 | 9.8% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $24,317 | 6 | 6.6% |
| Unspecified | $3,200 | 1 | 0.9% |
| Food and Beverage | $1,251 | 18 | 0.3% |
| Royalty or License | $167.28 | 1 | 0.0% |
Payments by Type
General
$366,962
145 transactions
Research
$3,200
1 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| PFIZER INC. | $128,093 | 37 | $0 (2024) |
| Seagen Inc. | $39,360 | 8 | $0 (2023) |
| CSL Behring | $35,635 | 18 | $0 (2024) |
| Octapharma USA, Inc. | $29,118 | 17 | $0 (2024) |
| SANOFI US SERVICES INC. | $27,378 | 10 | $0 (2024) |
| Boehringer Ingelheim International GmbH | $22,125 | 4 | $0 (2022) |
| Grifols, S.A. | $16,847 | 6 | $0 (2022) |
| MITSUBISHI TANABE PHARMA DEVELOPMENT AMERICA, INC. | $10,825 | 7 | $0 (2022) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $8,250 | 1 | $0 (2022) |
| Seattle Genetics, Inc. | $6,620 | 2 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $12,306 | 17 | MITSUBISHI TANABE PHARMA AMERICA, INC. ($4,167) |
| 2023 | $8,720 | 5 | Seagen Inc. ($5,120) |
| 2022 | $67,994 | 18 | PFIZER INC. ($30,985) |
| 2021 | $97,020 | 21 | PFIZER INC. ($46,475) |
| 2020 | $50,384 | 20 | SANOFI US SERVICES INC. ($17,173) |
| 2019 | $81,173 | 38 | PFIZER INC. ($28,214) |
| 2018 | $37,641 | 17 | CSL Behring ($20,545) |
| 2017 | $14,924 | 10 | PFIZER INC. ($5,890) |
All Payment Transactions
146 individual payment records from CMS Open Payments — Page 1 of 6
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/19/2024 | Octapharma USA, Inc. | PANZYGA (Biological) | Honoraria | Cash or cash equivalent | $750.00 | General |
| Category: IMMUNOLOGY | ||||||
| 07/04/2024 | Janssen Research & Development, LLC | — | Consulting Fee | Cash or cash equivalent | $250.00 | General |
| 06/24/2024 | ARGENX US, INC. | VYVGART (Drug) | Food and Beverage | In-kind items and services | $58.60 | General |
| Category: Immunology | ||||||
| 06/22/2024 | CSL Behring | Hizentra (Biological) | Food and Beverage | In-kind items and services | $27.28 | General |
| Category: Immunology | ||||||
| 05/23/2024 | ARGENX US, INC. | VYVGART (Drug) | Travel and Lodging | Cash or cash equivalent | $44.00 | General |
| Category: Immunology | ||||||
| 05/23/2024 | ARGENX US, INC. | VYVGART (Drug) | Travel and Lodging | Cash or cash equivalent | $26.80 | General |
| Category: Immunology | ||||||
| 05/23/2024 | ARGENX US, INC. | VYVGART (Drug) | Travel and Lodging | Cash or cash equivalent | $10.00 | General |
| Category: Immunology | ||||||
| 05/17/2024 | ARGENX US, INC. | VYVGART (Drug) | Consulting Fee | Cash or cash equivalent | $3,375.00 | General |
| Category: Immunology | ||||||
| 05/16/2024 | MITSUBISHI TANABE PHARMA AMERICA, INC. | — | Consulting Fee | Cash or cash equivalent | $1,000.00 | General |
| 05/16/2024 | MITSUBISHI TANABE PHARMA AMERICA, INC. | — | Consulting Fee | Cash or cash equivalent | $625.00 | General |
| 05/15/2024 | PFIZER INC. | TIVDAK (Biological) | Honoraria | Cash or cash equivalent | $1,440.00 | General |
| Category: Oncology | ||||||
| 05/06/2024 | SANOFI US SERVICES INC. | — | Consulting Fee | Cash or cash equivalent | $2,157.00 | General |
| 04/16/2024 | MITSUBISHI TANABE PHARMA AMERICA, INC. | — | Consulting Fee | Cash or cash equivalent | $167.00 | General |
| 04/16/2024 | MITSUBISHI TANABE PHARMA AMERICA, INC. | — | Consulting Fee | Cash or cash equivalent | $125.00 | General |
| 02/20/2024 | MITSUBISHI TANABE PHARMA AMERICA, INC. | — | Consulting Fee | Cash or cash equivalent | $1,500.00 | General |
| 02/20/2024 | MITSUBISHI TANABE PHARMA AMERICA, INC. | — | Consulting Fee | Cash or cash equivalent | $500.00 | General |
| 02/20/2024 | MITSUBISHI TANABE PHARMA AMERICA, INC. | — | Consulting Fee | Cash or cash equivalent | $250.00 | General |
| 10/24/2023 | Janssen Research & Development, LLC | — | Consulting Fee | Cash or cash equivalent | $1,000.00 | General |
| 06/28/2023 | Seagen Inc. | — | Consulting Fee | Cash or cash equivalent | $640.00 | General |
| 01/30/2023 | PFIZER INC. | — | Consulting Fee | Cash or cash equivalent | $1,950.00 | General |
| 01/26/2023 | Alnylam Pharmaceuticals Inc. | — | Consulting Fee | Cash or cash equivalent | $650.00 | General |
| 01/18/2023 | Seagen Inc. | TIVDAK (Biological) | Consulting Fee | Cash or cash equivalent | $4,480.00 | General |
| Category: Oncology | ||||||
| 12/09/2022 | PFIZER INC. | — | Consulting Fee | Cash or cash equivalent | $6,010.00 | General |
| 11/28/2022 | PFIZER INC. | — | Consulting Fee | Cash or cash equivalent | $4,225.00 | General |
| 11/22/2022 | MITSUBISHI TANABE PHARMA DEVELOPMENT AMERICA, INC. | — | Consulting Fee | Cash or cash equivalent | $1,500.00 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| TANEZUMAB CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $3,200 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2022 | 5 | 143 | 167 | $54,329 | $12,870 |
| 2021 | 10 | 359 | 420 | $130,072 | $35,396 |
| 2020 | 11 | 342 | 404 | $117,708 | $28,026 |
Total Patients
844
Total Services
991
Medicare Billing
$76,292
Procedure Codes
27
All Medicare Procedures & Services
27 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 39 | 47 | $16,967 | $5,307 | 31.3% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 34 | 34 | $17,544 | $4,850 | 27.6% |
| 95910 | Nerve conduction, 7-8 studies | Facility | 2022 | 18 | 18 | $4,518 | $1,400 | 31.0% |
| 95885 | Needle measurement of electrical activity in arm or leg muscles, limited study | Facility | 2022 | 39 | 55 | $12,375 | $803.22 | 6.5% |
| 95886 | Needle measurement of electrical activity in arm or leg muscles, complete study | Facility | 2022 | 13 | 13 | $2,925 | $509.21 | 17.4% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 64 | 88 | $31,768 | $10,772 | 33.9% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 68 | 68 | $35,088 | $10,327 | 29.4% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 16 | 19 | $6,859 | $2,329 | 34.0% |
| 95912 | Nerve transmission studies, 11-12 studies | Facility | 2021 | 17 | 17 | $6,137 | $2,241 | 36.5% |
| 95910 | Nerve transmission studies, 7-8 studies | Facility | 2021 | 23 | 23 | $5,773 | $2,103 | 36.4% |
| 95911 | Nerve transmission studies, 9-10 studies | Facility | 2021 | 18 | 18 | $5,418 | $2,083 | 38.4% |
| 95885 | Needle measurement and recording of electrical activity of muscles of arm or leg limited study | Facility | 2021 | 70 | 104 | $23,400 | $1,665 | 7.1% |
| 95886 | Needle measurement and recording of electrical activity of muscles of arm or leg complete study | Facility | 2021 | 39 | 39 | $8,775 | $1,477 | 16.8% |
| 95909 | Nerve transmission studies, 5-6 studies | Facility | 2021 | 19 | 19 | $3,439 | $1,238 | 36.0% |
| 95908 | Nerve transmission studies, 3-4 studies | Facility | 2021 | 13 | 13 | $1,963 | $697.92 | 35.6% |
| 95907 | Nerve transmission studies, 1-2 studies | Facility | 2021 | 12 | 12 | $1,452 | $464.70 | 32.0% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Facility | 2020 | 54 | 54 | $27,864 | $7,804 | 28.0% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 52 | 63 | $22,743 | $5,354 | 23.5% |
| 95912 | Nerve transmission studies, 11-12 studies | Facility | 2020 | 26 | 26 | $9,386 | $3,583 | 38.2% |
| 95910 | Nerve transmission studies, 7-8 studies | Facility | 2020 | 28 | 28 | $7,028 | $2,677 | 38.1% |
| 95885 | Needle measurement and recording of electrical activity of muscles of arm or leg limited study | Facility | 2020 | 73 | 118 | $26,550 | $1,909 | 7.2% |
| 95886 | Needle measurement and recording of electrical activity of muscles of arm or leg complete study | Facility | 2020 | 39 | 45 | $10,125 | $1,733 | 17.1% |
| 95911 | Nerve transmission studies, 9-10 studies | Facility | 2020 | 15 | 15 | $4,515 | $1,637 | 36.3% |
| 95909 | Nerve transmission studies, 5-6 studies | Facility | 2020 | 18 | 18 | $3,258 | $1,277 | 39.2% |
| 95908 | Nerve transmission studies, 3-4 studies | Facility | 2020 | 14 | 14 | $2,114 | $767.42 | 36.3% |
About Dr. David Cornblath, M.D
Dr. David Cornblath, M.D is a Neurology healthcare provider based in Lutherville, Maryland. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/27/2006. The National Provider Identifier (NPI) number assigned to this provider is 1801843834.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. David Cornblath, M.D has received a total of $370,162 in payments from pharmaceutical and medical device companies, with $12,306 received in 2024. These payments were reported across 146 transactions from 24 companies. The most common payment nature is "Consulting Fee" ($254,632).
As a Medicare-enrolled provider, Cornblath has provided services to 844 Medicare beneficiaries, totaling 991 services with total Medicare billing of $76,292. Data is available for 3 years (2020–2022), covering 27 distinct procedure/service records.
Ad
Practice Information
- Specialty Neurology
- Location Lutherville, MD
- Active Since 05/27/2006
- Last Updated 02/05/2013
- Taxonomy Code 2084N0400X
- Entity Type Individual
- NPI Number 1801843834
Products in Payments
- Hizentra (Biological) $28,743
- PANZYGA (Biological) $24,648
- VYNDAQEL (Drug) $23,014
- TIVDAK (Biological) $8,160
- NO PRODUCT DISCUSSED (Drug) $8,048
- KIG 10 (Drug) $5,544
- OCTAGAM IMMUNE GLOBULIN (HUMAN) (Drug) $3,900
- VYVGART (Drug) $3,514
- Gamunex-C (Biological) $3,131
- SPIRIVA RESPIMAT (Drug) $2,250
- Privigen (Biological) $1,973
- ERAXIS (Drug) $1,600
- ADCETRIS (Biological) $1,500
- CUTAQUIQ (Biological) $51.50
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.